Scheduling

Virtual visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More

COVID-19 Updates

COVID-19 Updates: Get the latest on vaccine information, in-person appointments, virtual visits and more. Learn More
Open menu
Close menu

Services

Search

Clinical Trials and Novel Therapies

Search our featured clinical trials & novel therapies



 

Featured Immunotherapy Trials and Novel Therapies

Administration of rapidly generated LMP, BARF1 and EBNA1 specific cytotoxic T-lymphocytes to patients with EBV-positive lymphoma

GINAKIT2 - Treatment for neuroblastoma (H-41033)

KYMRIAH®: The first FDA-approved gene therapy for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL)

New immunotherapy for children with hepatoblastoma or hepatocellular carcinoma

Vaccination to enhance the antitumor activity of GD2 chimeric antigen receptor expression VZV-specific T cells in subjects with advanced sarcomas

Administration of Her2 Chimeric Antigen Receptor Expressing T Cells for subjects with advanced sarcoma (HEROS)

Featured Leukemia Trials and Novel Therapies

AALL15P1: Azacitidine and combination chemotherapy in treating infants with acute lymphoblastic leukemia and KMT2A gene rearrangement

AALL1131: Combination chemotherapy in treating young patients with newly-diagnosed high-risk B acute lymphoblastic leukemia and Ph-like TKI sensitive mutations

AALL1231: Combination chemotherapy with or without Bortezomib in treating younger patients with newly-diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma

AALL1331: Blinatumomab in treating younger patients with relapsed B-cell acute lymphoblastic leukemia

AALL1621: Inotuzumab Ozogamicin in treating younger patients with relapsed or refractory CD22 positive B acute lymphoblastic leukemia

AAML1531: Response-based chemotherapy in treating newly-diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome

ADVL1411 — A Phase I/II study of BMN673 plus Temozolomide

AflacLL1602 ENCERT

Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells (CRIMSON)

Efficacy and Safety of Daratumumab in Pediatric and Young Adults With Relapsed or Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

T2016-003: Epigenetic Reprogramming in Relapsed/Refractory AML

KYMRIAH®: The first FDA-approved gene therapy for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL)

TACL-CFZ008 - Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

TACL-T2012-002: Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL

TACL-2014-001: A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)

Featured Retinoblastoma Trials

Featured Solid Tumor Trials

9-ING-41 in Pediatric Patients With Refractory Malignancies

A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors (FIREFLY-1)

Administration of Her2 Chimeric Antigen Receptor Expressing T Cells for subjects with advanced sarcoma (HEROS)

A Phase II trial of Avelumab, a fully human antibody that targets cells expressing PD-L1, in patients with recurrent or progressive osteosarcoma

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma (CLOVER-2)

GINAKIT2 - Treatment for neuroblastoma (H-41033)

PEPN2111 A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma

New immunotherapy for children with solid tumors including liver, kidney and additional rare cancers

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors (PIRATE)

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Clinical trials for patients with Ewing sarcoma

Featured Thyroid Cancer Trials

Featured Vascular Anomalies Trials

EPIK-P2 (CBYL719F12201) / EPIK-P2: A Phase II double-blind study with an upfront, 16- week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)

  • Subjects will be identified from the population of patients diagnosed with PIK3CA-related Overgrowth Spectrum (PROS), receiving medical care from the Cancer and Hematology Center and Vascular Anomalies Center at Texas Children’s Hospital. Up to ten (10) patients will be enrolled overall.
  • Participants will be enrolled into two age groups: Group 1: ≥ 18 years old and Group 2: 6-17 years old.
  • All Sexes are Eligible

MK705-006 / A Multicenter, Open-label, Phase 2 Extension Trial to Study the Long-Term Safety in Participants With PROS or Proteus Syndrome Who Are Currently Being Treated with Miransertib in Other Studies

  • Subjects will include participants with PROS or PS who are currently receiving miransertib as part of Study MK-7075-002 (also known as the MOSAIC study or ArQule’s compassionate use/expanded access program. At our site participants will enter this study as an extension of the ARQ MOSAIC study.
  • All Sexes are Eligible

Anticoagulation Effects on Quality of Life in Patients with Slow-flow Vascular Malformations

  • Presence of a slow-flow vascular malformation
  • ≥2 years old to 99 years old
  • Determined to need and eligible for anticoagulation therapy at the discretion of the treating physician per standard of care
  • Informed consent provided, and if applicable, child assent provided
  • All Sexes are Eligible
 
For a complete list of clinical trials offered at Texas Children's Hospital, visit clinicaltrials.gov
Clinical Trials and Novel Therapies

As a recognized leader in clinical and laboratory research, Texas Children’s Cancer and Hematology Center offers clinical trials for a wide range of children’s cancer and blood disorders. The trials we offer are the result of physician scientists pioneering the translation of breakthrough research findings from the laboratory to the clinic.

We have over 350 researchers in 47 laboratories performing cutting-edge research and over 250 active therapeutic clinical trials, many of which are only available at Texas Children’s. We work closely with the pharmaceutical industry to make important new agents available for children with cancer and blood disorders.

Our physicians develop trials and participate in all major pediatric cancer and blood disorder cooperative clinical trial groups, like the Children’s Oncology Group (COG) and the Pediatric Brain Tumor Consortium (PBTC).

Over 80% of our patients are involved in a clinical trial or study since research shows that children treated on a clinical trial have better outcomes. Every eligible patient is considered for entry in National Cancer Institute-approved trials, and the vast majority are registered in these studies.  We work closely with referring physicians and families to identify appropriate options for each individual child and to support the child and the whole family through the entire treatment process.

Interested in learning more?

FAQs about clinical trials